Luc/RFP Reporter Cell Line-A375

https://pmc.ncbi.nlm.nih.gov/articles/PMC12801355/

The Researchers examined the in vivo interactions of self-assembled peptide amphiphile (PA) nanostructures with endogenous biomolecules to evaluate their potential for broad tumor targeting. Using a modular PA construct, SA‑E, they assessed cellular uptake, biodistribution, and therapeutic delivery across multiple human, murine, and patient-derived tumor models, including HCT‑116, A375, MCF7, 4T1, RG2, LL/2, and various transgenic and xenograft models. Cell lines were cultured under standard conditions with verified mycoplasma-free status, and select lines were transfected with lentivirus-expressed mCherry for membrane labeling. SA‑E facilitated tumor accumulation by dynamic assembly with circulating lipoproteins and interaction with cancer cell membranes, enabling imaging and chemotherapy delivery while minimizing off-target effects.

Figure 1. IVIS imaging demonstrates SA‑E accumulation across multiple solid tumor models, with strong concordance between ICG-labeled PA signal and tumor sites, including xenografts, patient-derived tumors, and transgenic lesions. (Xiang L, et al., 2026)

Creative Biogene–sourced human and murine cancer cell lines, along with reliable lentiviral tools for fluorescent labeling, support the development and evaluation of modular nanomaterials like SA‑E. These platforms enable mechanistic studies of tumor targeting, biodistribution, and therapeutic delivery in diverse preclinical models.